Unichem Labs Appoints Dr. Swati Patankar as Independent Director, Q3 FY26 Results Approved
Unichem Laboratories approved Q3 FY26 results. Consolidated revenue was ₹521.17 crore, with profit after tax at ₹264.29 crore. Standalone revenue was ₹314.90 crore, with profit after tax at ₹216.11 crore. Dr. Swati Patankar was appointed as Non-Executive Independent Director for five years, effective February 5, 2026.
The appointment of a new director is a significant corporate governance event. The financial results show strong profitability, which impacts investor perception.
The appointment of an independent director with significant experience and the strong profit growth in the quarterly results contribute to a positive sentiment.
Unichem Laboratories Limited announced the approval of its Unaudited Financial Results (Standalone & Consolidated) for the third quarter and nine months ended December 31, 2025. The Board of Directors, in its meeting held on February 5, 2026, also approved the appointment of Dr. (Ms.) Swati Patankar as a Non-Executive Independent Director for a term of five consecutive years, effective February 5, 2026, subject to shareholder approval.
Dr. Patankar brings over 35 years of experience in academia and research, with a Ph.D. in Molecular Microbiology from Tufts University, USA. She has held significant administrative roles at IIT Bombay, including Dean of International Relations, and has been involved with the World Health Organization (WHO) TDR Working Group. Her expertise spans drug discovery, drug delivery, and academic mentoring. Her appointment will be subject to a postal ballot by shareholders, with Mr. Alwyn Dsouza or Mr. Jay D’Souza appointed as Scrutinizers for the process.
The company's consolidated results for the quarter ended December 31, 2025, show a revenue from operations of ₹521.17 crore, a decrease from ₹578.96 crore in the previous quarter. Profit after tax for the quarter stood at ₹264.29 crore, a significant increase from a loss of ₹11.89 crore in the same period last year. The nine-month period ended December 31, 2025, reported a consolidated profit after tax of ₹241.93 crore on revenues of ₹1,626.73 crore.
Standalone results for the quarter ended December 31, 2025, show revenue from operations at ₹314.90 crore, down from ₹447.83 crore in the corresponding quarter of the previous year. The standalone profit after tax for the quarter was ₹216.11 crore, a substantial rise from ₹46.89 crore in the prior year's quarter. For the nine months ended December 31, 2025, standalone profit after tax was ₹174.33 crore on revenues of ₹1,056.05 crore.
Notable exceptional items for the quarter included a net loss of ₹275.52 crore on the disposal of land & building and interest on a European commission fine. The Board meeting commenced at 12:30 p.m. and concluded at 3:00 p.m. on February 5, 2026.
What to do with a filing like this
Unichem Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Unichem Laboratories Limited. Read the original for the full detail.